SB

Supriya Bhattacharjee

Director Director DIN 07601265
DIN 07601265 First appointment Sep 2016 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Sep 2016
Shareholding value •••• Premium profile

About Supriya Bhattacharjee

Data last updated:

Supriya Bhattacharjee was a Director at Synthico Drugs & Pharmaceuticals Private Limited (2016–2018) and Director at Medigift Pharmaceuticals Private Limited (2016–2020). The companies operate in Trading and Pharma.

DIN 07601265
Primary Designation Director
Industry Trading
First Appointment 19 Sep 2016

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director27 Oct 20162016Under Process Of Striking Off
Director19 Sep 20162016₹4.4 Lakh (FY 2020)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Synthico Drugs & Pharmaceuticals Private Limited
Medigift Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Supriya Bhattacharjee

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Supriya Bhattacharjee

Supriya Bhattacharjee was first appointed on 19 Sep 2016 as Director at Medigift Pharmaceuticals Private Limited.

Supriya Bhattacharjee held 2 earlier board appointments: Synthico Drugs & Pharmaceuticals Private Limited (Director, 27 Oct 2016 to 19 Dec 2018); Medigift Pharmaceuticals Private Limited (Director, 19 Sep 2016 to 01 Dec 2020).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available